🔗 Share this article

Given that the United States continues making sweeping revisions to its vaccination schedules, a particular individual has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 vaccinations throughout the global health crisis and has zeroed in on possible deaths following Covid immunization in her short position at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities planned to reveal major revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of step with a large portion of the global community with little proof for benefit. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting some childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

So far statements, she has continued to focus on immunizations – typically the domain of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Qualifications

Dr. Høeg has little discernible track record in drug development, oversight or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Past heads of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who ran CBER have had.”

CDER has an vast portfolio at the FDA, the former commissioner pointed out.

“Everybody just focuses on the new drug program, but the off-patent medication office clears a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and more, and every single one need to be managed,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant management aspect to the position, which supervises in excess of 5,000 employees. “It is a massive leadership role, if you perform it correctly,” she said.

Agency Reaction and Contentious Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among agency officials on vaccines, a press secretary said that the “inquiries rely on flawed premises”.

“Her resume is consistent with the functions of her role,” the spokesperson explained, noting the period Høeg spent advising the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial rapid medication authorization process that reportedly worried her former heads. “How are these medications being selected for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”

Established History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, track record, some experts observe. She released a study using unverified public submissions to determine the incidence of myocarditis after COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new administration featured altering guidelines for recently developed shots and ending “non-essential” immunizations, she remarked post-election on a online show. At the agency, Høeg has according to sources proposed preventing young men from getting Covid vaccines.

“She is an complete dogmatist who begins with her beliefs and tailors the evidence to retrofit the data in a extremely deceptive, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|